Pneumonia of Viral Etiologies by Sameera, Al Johani & Javed, Akhter
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 8
Pneumonia of Viral Etiologies
Al Johani Sameera and Akhter Javed
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.71608
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Al Johani Sameera and Akhter Javed
Additional information is available at the end of the chapter
Abstract
Pneumonia is a common illness that continues to cause significant morbidity and mortal-
ity in both adults and children. Bacteria such as Streptococcus pneumonia, Staphylococcus 
aureus and Haemophilus influenzae are generally considered as the main pathogens in 
community-acquired pneumonia and Legionella species, Chlamydia pneumoniae and 
Mycoplasma pneumonia in atypical pneumonias. In contrast the proportion of pneumonias 
due to viruses has been both difficult to detect and quantify with any precision. However, 
with the advent of powerful molecular techniques and rapidly developing technologies a 
greater number of viruses are being implicated as pathogens and co-pathogens in pneu-
monia. In the case of adults, the most commonly detected viruses are influenza virus, 
RSV and parainfluenza. Other viruses that have recently received considerable attention, 
are H5N1 influenza virus and coronaviruses. Infectious causes of pneumonia in immu-
nocompromised patients include measles, HSV, CMV, HHV-6 and Influenza viruses. 
Pneumonias caused by other viruses are more rarely reported and include outbreaks of 
rhinovirus, adenovirus (particularly serotype 14 in military institutions), coronavirus, 
and metapneumovirus. A range of promising therapeutic targets have been identified 
and numerous innovative therapeutic treatments demonstrated to improve lung injury 
due to viral infections.
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1. Introduction
Pneumonia was once known as Winter Fever and is an acute infection and inflammation of 
the lung parenchyma. It was first described by Hippocrates around 460 BC [1] . However, it 
wasn’t until the 19th century that pneumonia was established as a true infection, and not just 
a symptom of other diseases. Edwin Klebs a German pathologist in 1875 observed bacteria 
under a microscope in cases of pneumonia [2]. Then, Carl Friedlander and Albert Frankel in 
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1884 and 1884 respectively identified two of the most common bacterial causes of pneumonia, 
Streptococcus pneumoniae and Klebsiella pneumonia [3]. By the 1930s, treatment for pneumonia 
had been developed with the introduction of penicillin playing a key role.
Pneumonia remains the leading cause of childhood mortality under the age of 5 and the 
most common reason for adult hospitalisation in low and middle income countries, despite 
advances in preventative and management strategies [4]. Pneumonia usually causes symp-
toms for 3–4 weeks, and daily activities may be impaired for a further 3 weeks on average. 
Community-acquired pneumonia (CAP) refers to pneumonia acquired outside of hospitals or 
extended-care facilities. Nosocomial pneumonia and hospital-acquired pneumonia describe 
infections acquired in the hospital setting. These are usually defined as pneumonia that occurs 
48 h or more after hospital admission, and which was not incubating at the time of admission. 
Community-acquired pneumonia continues to be a significant health issue [5]. Annually in 
the United States there are around 4 million cases of which 20% of cases may require hospital-
ization. As a result there are more than 65 million days of reduced activity overall. Mortality 
rates can range from 1 to 30% making it the sixth leading cause of death [6]. In developing 
countries pneumonia is either the first or second leading cause of death. In Europe, around 
14.4 per 10,000 children aged over 5 years and 33.8 per 10,000 under 5 years are diagnosed 
with CAP. CAP is more common in the developing world, estimated at 0.28 episodes per 
child per year and accounting for 95% of all cases [7].
2. Pathophysiology
Pneumonia is an inflammatory process in lung parenchyma most commonly caused by bacte-
ria and viruses. Less common etiologies include mycoplasma, fungi and parasites. Organisms 
spread to the lungs through aerosolization, aspiration, or hematogenous spread due to inha-
lation of droplet or by aspiration of fluids in the oropharynx [8] Pneumonia results if host 
defense mechanisms are unable to keep the respiratory network infection free. The patho-
physiology varies depending on etiology. In the case of bacterial pneumonia there is an intra-
alveolar suppurative exudate with consolidation [9].
In the case of viral pneumonia there is an inflammatory interstitial inflammation with infil-
trate in the alveolar, causing damage to ciliated epithelium surfaces. The lungs become con-
gested, hemorrhagic and Intracellular viral inclusions may form. Local host defenses, such 
as mucociliary clearance, or secretion of specific secretory IgA antibodies can remove some 
of the virus particles. However, if mucociliary clearance is impaired or secretory anti-influ-
enza IgA antibodies are absent, infection continues to spread. Respiratory epithelial cells are 
invaded, and viral replication occurs. Newer viruses then infect larger numbers of epithelial 
cells, shut off the synthesis of critical proteins, and ultimately lead to host cell death [10].
There can be numerous types of immune response depending on how cytokine is produced. For 
example, cell-mediated immunity is initiated in type 1, while type 2 cytokines are responsible for 
allergic responses. Children infected with respiratory syncytial virus (RSV) with more serious 
acute bronchiolitis often have impaired type 1 immunity or augmented type 2 immunity [11].
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Respiratory viruses such as RSV or rhinovirus that damage the respiratory tract cause release 
of multiple humoral factors, including leukotriene C4, and histamine. In the case of RSV virus-
specific immunoglobulin E is released. Rhinovirus infections can cause release of bradykinin, 
interleukin 1, interleukin 6, and interleukin 8. A further complication of RSV infections is that 
they can increase bacterial adherence to respiratory epithelium, impair mucociliary clearance, 
and cause changes in bacterial phagocytosis by host cells [12].
In co infections, secondary bacterial superinfection makes for a poor prognosis of the original 
viral infection [13]. Interleukin-10, is purported to attract large numbers of macrophages and 
neutrophils to the lung. The presence of these cytokines increases the immune response, caus-
ing inflammatory damage and preventing the proper removal of bacteria.
3. Epidemiology
Numerous studies by the WHO have estimated there are over 450 million cases of pneumo-
nia globally with approximately 3 million deaths particularly prone are the elderly and chil-
dren [14]. The annual rate of CAP increases from 6/1000 in the 18–39 age group to 34/1000 in 
75 years and over age group. Incident rates tend to be higher in colder climates of the North 
and hospitalization is required in 20–40% cases. In severe cases mortality can vary from 5 to 
10% of cases [15] .
Viral pneumonias are common in the Mideast. In an Iranian study viruses causing pneu-
monia were Influenza A (7.4%), influenza B (3.5%), RSV (12.9%), and adenovirus (5.9%). 
Parainfluenza-1,2 and 3 were 6.4, 6.4 and 15.8% respectively [16]. More recently, avian 
influenza has become endemic in some parts of the Middle East, especially Egypt and 
Turkey [17].
WHO data published in May 2014 Influenza and Pneumonia Deaths in Saudi Arabia reached 
5689 or 7.08% of total deaths. The age adjusted death rate is 44.89 per 100,000 of population 
[18]. Middle East respiratory syndrome is caused by a novel coronavirus (MERS-CoV) first 
isolated in the Kingdom of Saudi Arabia in 2012 from the respiratory tract secretions of a 
Saudi businessman who died from viral pneumonia [19]. Subsequently, cases were identi-
fied in patients living outside the Arabian Peninsula and the Middle East, who were infected 
either during a stay in the Middle East or by close contact with an individual from an endemic 
country. Most affected patients were previously healthy men with a median age of 50 years 
[20]. In 2016, the World Health Organization (WHO) published a report on 1698 laboratory-
confirmed cases of MERS-CoV infection. The mortality rate was 36%. All cases were directly 
or indirectly linked through residence or travel to Saudi Arabia, the UAE, Jordan, Qatar, 
Oman, Lebanon, Kuwait, Yemen, Egypt, and Iran. There were also reports of sporadic reports 
in other countries including the United Kingdom, France, Malaysia, Tunisia, Italy, Austria, 
Greece, Turkey, the United States of America, Germany, Philippines, and Thailand [21]. The 
largest outbreak of the virus outside its endemic region was recorded in 2015, in South Korea. 
One-hundred and eighty-six additional cases were confirmed, including the first in China, 
with a total of 36 deaths. MERS-CoV is a zoonotic virus that can lead to secondary human 
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infections. Dromedary camels are considered as the intermediate host, with closely related 
virus sequences in bats. Human-to-human transmission has been noted in households and 
health care setting. But community-wide transmission has not been observed [22].
3.1. Pneumonia in children
The World Health Organization (WHO) established the Child Health Epidemiology Reference 
Group (CHERG) to monitor the incidence of childhood [23]. In 2000, CHERG compiled pneu-
monia statistics in children under age 5. It was found that there were 150 million new cases 
of pneumonia in children under 5. Of these, approximately 4 million occurred in developed 
countries, while the majority occurred in developing nations [24]. Hospitalization rates for 
pneumonia were approximately 9%. More than half of all worldwide cases of childhood 
pneumonia occurred in just five countries: India, China, Pakistan, Indonesia, Nigeria and 
Bangladesh. Europe had the lowest rate (0.06 episodes per child-year), while Southeast Asia 
and Africa had the highest overall incidence rates (0.36 and 0.33 episodes per child-year, 
respectively). Factors that increased the risk of developing childhood pneumonia included low 
birth weight, malnutrition, crowded living quarters, indoor air pollution, insufficient breast 
feeding, and lack of vaccinations. Other possible contributing factors included pre-existing 
medical conditions such as asthma, and annual rainfall levels. Also, parents who smoked and 
lack of parent education [25].
3.2. Pneumonia in adults
Pneumonia is a serious concern in adults and viruses cause 15–30% of cases in immuno-
competent adults hospitalized with pneumonia [26]. Increased rates of pneumonia-associated 
hospitalizations have been reported in the United States, Denmark, United Kingdom, and 
the Netherlands. In 2010, approximately 1.1 million patients in the USA were hospitalized 
for pneumonia with an average length of hospital stay 5.2 days [27]. In the UK, the num-
ber of hospitalizations due to pneumonia increased by 34% during the period from 1997 to 
2005. This was particularly notable in older adults. Approximately 26,000 people died from 
pneumonia and influenza in England and Wales in 2013 according to national statistics. 
Contributing factors may be due to other chronic diseases such as heart disease, diabetes, and 
immunocompromised patients [28].
4. Atypical pneumonia
Atypical pneumonia refers to pneumonia caused by atypical bacteria, including Legionella 
species, Chlamydia pneumoniae and Mycoplasma pneumoniae [29]. It is called “atypical” because 
the symptoms and signs differ from those of pneumonia due to other common organisms. It 
is generally regarded that M. pneumoniae, Legionella spp., C. pneumoniae, Chlamydophila psittaci 
and Coxiella burnetii are the key CAP pathogens not readily identified by standard culture 
methods [30]. Other atypical pathogens include viruses, atypical mycobacteria, Francisella 
tularensis and an extensive list of agents of bioterrorism.
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4.1. Organisms that cause atypical pneumonias include
Mycoplasman pneumoniae, the most common atypical pneumonia organism spreads when some-
one carrying the infection comes in close contact with others. The condition, also known as 
“walking pneumonia,” is generally mild and seen in the outpatient setting. It appears to occur 
mostly in school-aged children and young adults. Less common is Chlamydia pneumoniae which 
causes 10% of all CAP cases and is usually mild but usually more severe in the elderly [31]. 
Legionella pneumophila causes Legionnaires’ disease commonly found in hotels, cruise ships, 
hospitals and commercial buildings, where people come into contact with contaminated drop-
lets from cooling towers and evaporative condensers. Other reports of infection have been noted 
near whirlpools and saunas [32]. It is believed the organism causes up to 4% of all pneumonia 
cases. Known viral causes of atypical pneumonia include respiratory syncytial virus (RSV), 
influenza A and B, parainfluenza, adenovirus, severe acute respiratory syndrome (SARS) and 
measles [33].
5. Viral pneumonia
The advent of molecular diagnostics has greatly improved the identification of viruses in 
patients with CAP. Over the last decade, several studies have used PCR to establish the 
importance of viruses in the etiology of CAP. Globally, it is estimated that 200 million cases of 
viral pneumonia occur annually. Most commonly are influenza viruses (A and B), parainflu-
enza viruses 1, 2 and 3, rhinoviruses, and coronaviruses [34].
Viral pneumonia prevails mostly in young children and older adults. Etiologies include 
influenza, adenovirus, parainfluenza, H1N1 and respiratory syncytial virus (RSV). Influenza 
A and B occurs in the winter and spring. Symptoms include, headache, fever, and muscle 
aches. Respiratory syncytial virus (RSV) is most common in the spring and infects young 
children. Adenovirus and parainfluenza viral pneumonias exhibit cold symptoms (runny 
nose and conjunctivitis). Post-influenza pneumonia is often accompanied by secondary bac-
terial infection due to Staphylococcus pneumoniae and Staphylococcus aureus. Pneumonia in 
immunocompromised patients is attributed to measles, HSV, CMV, HHV-6 and Influenza 
viruses. There is also an increased risk of secondary bacterial lower respiratory tract infec-
tion (LRTI). The known complication following influenza infection is Staphylococcus aureus 
pneumonia [35].
Respiratory syncytial virus (RSV) has been identified as an important cause of pneumonia in 
adults, especially in the elderly. The rate of RSV, overall is between 2 and 5% throughout the year 
and between 5 and 14% during winter. Adults with severe immunodeficiency are at particular 
risk of severe RSV infection [36].
Viral pneumonia infections include both DNA and RNA viruses. Some are well-known lung 
pathogens that produce common clinical and radiologic manifestations. Others are rarely 
involved as lung pathogens. Many viruses can cause pneumonia, either directly or indirectly. 
They include:
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5.1. Adenoviruses
Adenoviruses are enveloped DNA viruses and a diverse group that cause a wide spectrum 
of clinical illnesses. At least 52 serotypes exist, classified into 7 subgroups or species (A-G). 
Adenovirus pneumonia typically is limited to newborns, immunocompromised hosts, and 
school or military camp populations. Severe adenovirus pneumonia has been more commonly 
described in immunocompromised patients. Respiratory infection in immunocompetent 
patients is usually self-limited and mild [37]. However, with advances in molecular techniques, 
adenovirus has been increasingly discovered to be involved in sporadic cases and in severe 
CAP in healthy adults. Pulmonary disease is predominantly caused by serotypes 1, 2, 3, 4, 5, 7, 
14, and 21. Adenovirus infection accounts for up to 20% of childhood pneumonias, primarily 
in those children younger than 5 years of age, but such pneumonias occur infrequently in the 
non-military adult population. Types 4 and 7 viruses can cause outbreaks of respiratory disease 
in military recruits, whereas Type 7 viruses can cause bronchiolitis and pneumonia in infants. 
A virulent strain of Adenovirus, serotype 14 (subgroup B) has been reported to cause greater 
symptoms of respiratory illness and pneumonia. It was first observed in 2005 among civilian 
and military populations. Outbreaks occurred subsequently at military academies throughout 
the United States and in the Pacific Northwest [38].
5.2. Coronavirus
Coronaviruses are from the family Coronaviridae and are single-stranded RNA viruses. As the 
name indicates the surface is covered by crown like projections. This virus is spread via droplet 
and fomite exposure. Coronaviruses were not thought to significantly cause pneumonia until 
recently. However, the severe acute respiratory syndrome (SARS) pandemic in 2003 brought 
the ability of this virus to cause life-threatening pneumonia to worldwide attention.
There are six human coronaviruses (HCoVs) that are established human pathogens with world-
wide distribution, causing upper and lower respiratory tract infections: HCoV-229E, OC43, 
HKU1, NL63, MERS-COV (Middle East respiratory syndrome) and SARS-COV (severe acute 
respiratory syndrome) [39].
MERS-COV was first identified in Saudi Arabia in September 2012, approximately 2000 MERS-
CoV cases have been detected in over 20 countries. The newly reported cases lift Saudi Arabia’s 
MERS-CoV total since the virus was first detected in humans in 2012 to 1598 cases, 661 of them 
fatal and the majority of MERS-CoV cases continue to be reported from the Middle East. The 
source of the virus has remained a mystery but transmission and virological studies point 
toward dromedary camels in the Middle East by which humans may become infected through 
zoonotic transmission. Human-to-human transmission is then exacerbated through close 
household contacts and in healthcare settings [40].
5.3. Cytomegalovirus
Cytomegalovirus (CMV) is a herpesvirus that is a common cause of infections. In hosts who 
are immunocompetent, acute CMV infection causes a mononucleosis-like syndrome. CMV 
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pneumonia may occur and is often fatal in immunocompromised individuals, primarily 
hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients. The 
severity of pneumonia is related to the extent of immunosuppression [41]. CMV pneumonia 
has a prevalence of 15% and a mortality rate of approximately 85% in cancer patients receiv-
ing allogeneic bone marrow transplants. The major risk factor for CMV pneumonia in these 
patients is acute graft-versus-host disease.
Pneumonia is the most common presentation of CMV disease following lung transplantation 
CMV infection in lung transplant recipients is approximately 50%. Lung is a CMV latency site 
and viral reactivation has been associated with direct systemic infection and indirect effects 
such as acute rejection. The risk of CMV infections in these cases is dependent on the immu-
nosuppressive therapy and serologic status of the donor and recipient.
Moreover CMV pneumonia is identified to be a predictive factor for the later development 
of chronic rejection in lung transplant. Several studies have been carried to find the optimal 
preventive strategy to avoid CMV infection after lung transplantation. An effective treatment 
strategy has been valganciclovir prophylaxis for at least 180 days following combined pro-
phylaxis together with ganciclovir and CMV-immune globulin (CMV-IG) [42].
5.4. Epstein-Barr virus
Epstein-Barr virus (EBV) is well-known to be transmitted through infected saliva. The virus can 
cause pneumonia without mononucleosis. Lung involvement secondary to EBV infections usu-
ally only occurs in immunocompromised people. However, in 25% of pediatric patients with HIV 
infection, the virus can cause lesions due to lymphocytic interstitial pneumonia or pulmonary 
lymphoid hyperplasia.
Infectious mononucleosis occurs in young adults aged 15–30 years and usually resolves with-
out sequelae. This disorder may cause chronic tiredness and fevers but can also be compli-
cated by life-threatening problems. Pulmonary involvement associated with Epstein-Barr 
virus infection is uncommon but can occur as a complication of infectious mononucleosis. 
Pathologically, mononuclear inflammatory cells are evident along interlobular septa in inter-
stitial pulmonary infiltrates [43].
5.5. Herpes simplex virus
Herpes simplex virus (HSV) is primarily implicated in severely immunocompromised patients 
primarily, e.g., solid organ transplant recipients, patients who are undergoing chemotherapy 
or are neutropenic, or those who have congenital immunodeficiency. Herpes simplex virus is 
spread by viral shedding from asymptomatic excreters or from active lesions. It is a rare cause 
of lower respiratory tract infections. HSV pneumonia can occur as a secondary infection to 
upper airway infection or following viremia due to genital or oral lesions [44]. Herpes simplex 
virus can also cause pneumonia in compromised hosts, with a mortality rate of 80%.
Herpes simplex virus type 1 pneumonia is relatively uncommon that generally affects patients 
who are immunocompromised. It often occurs as a polymicrobial infection and is frequently 
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associated with coexisting bacterial pneumonia. Pneumonia is usually characterized by a pro-
teinaceous exudate and alveolar necrosis. There is a variable polymorphonuclear inflammatory 
response [45].
5.6. Human metapneumovirus
Human metapneumovirus (hMPV) is in the Paramyxoviridae family and was initially 
described in the Netherlands in 2001 [46]. It is a pleomorphic-shaped virus with protein pro-
jections from the surface. hMPV is a ubiquitous organism and almost all children have been 
exposed to it by age 5 years, Morbidity in lower respiratory tract infections in children and 
infants was reported to bronchiolitis (59%), croup (18%), asthma (14%), and pneumonia (8%) 
[47]. Reinfection continues to occur throughout life. The virus is spread via droplet and fomite 
exposure.
The severity of infection increases with older age and with complications such as immu-
nosuppressive conditions or cardiopulmonary disease. Adult hospitalizations with hMPV 
infection are associated with chronic obstructive pulmonary disease (COPD) exacerbations, 
pneumonia and bronchitis. Severe pneumonitis requiring intensive care is required in immu-
nocompromised hosts (e.g., hematologic malignancies).
5.7. Influenza virus
The influenza viruses are RNA viruses in the family Orthomyxoviridae, they are enveloped, 
single-stranded, and are the most common viral cause of pneumonia. Influenza has three 
serotypes A, B, and C. Influenza type A can infect livestock allowing a reservoir for infec-
tion and opportunity for epidemics in humans. For this reason it is usually the most virulent 
pathogen. The structure of influenza virus includes two envelope glycoproteins, known as 
hemagglutinin (H) and neuraminidase (N).The hemagglutinin enables infectivity of the virus 
by attaching to cellular sialic acid residues, whereas the N protein allows spread of the virus 
to other cells through cleavage of the new virus. Severe pneumonia complications can occur 
in high-risk individuals [48]. Two influenza types have emerged of particular importance: 
H5N1 avian influenza strain and the novel H1N1 swine influenza strain. In the influenza 
A (H1N1) pandemic of 2009–2010, the World Health Organization estimated approximately 
16,000 deaths. The majority of these deaths corresponded to patients with underlying risk 
factors contributing to worse outcomes Influenza type B causes illness seems to occur more 
in closed populations, e.g., boarding schools. Influenza type C is less common and occurs as 
sporadic cases [49].
5.8. Measles virus
Measles is a respiratory tract virus that causes a febrile illness with rash in children and a 
mild pneumonia in healthy adults. It is a single-stranded RNA virus in the Paramyxoviridae 
family and the genus Morbillivirus. It comprises a nucleocapsid surrounded by an envelope. 
Measles is a highly contagious disease that results from infection with measles virus and is 
still responsible for more than 100,000 deaths every year [50]. Measles virus is transmitted by 
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the respiratory route and illness begins with fever, cough, coryza. Complications of measles 
affect most organ systems, with pneumonia accounting for most measles-associated morbidity 
and mortality.
Pulmonary disease from measles virus infection can occur as a primary measles virus pneumo-
nia with secondary bacterial pneumonia or as an atypical measles virus pneumonia. Measles 
virus can cause pneumonia in 3–4% of infected patients mostly with secondary bacterial infec-
tion such as Haemophilus influenzae and Neisseria meningitides. The prevalence of measles 
virus pneumonia is higher in immunocompromised patients and pregnant women. Measles 
virus pneumonia without a secondary bacterial infection appears with diffuse alveolar dam-
age and epithelial hyperplasia. Epithelial hyperplasia is seen in bronchioles and peribronchial 
alveoli as well as in the tracheobronchial epithelium with cystic dilatation of mucous glands. 
Histologically, measles virus pneumonia displays multinucleated giant cells containing up to 
50 nuclei within the bronchiolar and tracheobronchial epithelium [51].
5.9. Parainfluenza virus
Parainfluenza virus (PIV) consists of nucleocapsids, which propagate in the cytoplasm of 
infected cells, with hemagglutinin present in the virion envelope. PIV is a common virus 
infection of childhood. PIV is second in importance to only RSV in causing children pneumo-
nia and bronchiolitis in infants younger than 6 months and lower respiratory tract disease. 
Transmission is through direct contact or large-droplet spread.
Although there are four subtypes of PIV, PIV types 1 and 2 tend to peak during the fall season 
where as type 3 is endemic year-round. Recurrent upper or lower respiratory tract infections 
occur throughout life because Immunity is short term. The infections vary from a self-limit-
ing illness to life-threatening pneumonia especially in immunocompromised hosts leading 
to lung injury and respiratory failure [52]. In one study, hematopoietic stem cell transplant 
(HSCT) patients with PIV progressed to develop pneumonia. Of 44% of these patients with 
pneumonia there was a mortality rate of 37% [53].
5.10. Respiratory syncytial virus
Respiratory syncytial virus (RSV) consists of only one serotype and is in the Paramyxoviridae 
family. Structurally, it consists of 10 viral polypeptides, 4 of which are associated with virus 
envelope, and 2 of these (F and G) are important for infectivity and pathogenicity. RSV is 
highly contagious, spreading via droplet and fomite exposure. RSV is the most frequent cause 
of lower respiratory tract infections among infants and children and the second most com-
mon viral cause of pneumonia in adults [54]. The majority of children are infected by the 
age of 5 years in settings such as daycare centers but the resulting immunity is incomplete. 
Reinfection when it occurs in older children and young adults is mild. But, with advanc-
ing age there is a greater likelihood severe disease and pneumonia. Diagnosed adult RSV 
hospitalizations have increased significantly in the United States. Respiratory syncytial virus 
hospitalizations appear to be greater in severity than influenza hospitalizations, especially 
immunocompromised and in older adults [55].
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5.11. Rhinovirus
Many reports from the literature report that rhinovirus accounts for approximately 30% of 
cases of all virus-related pneumonia. Rhinovirus is considered the second most frequently 
recognized agent associated with pneumonia and bronchiolitis in the young. The virus is 
associated with asthma hospitalizations in both old and young patients [56].
Rhinovirus is genetically diverse with more than 100 serotypes identified. In addition to com-
mon colds, reports have suggested that rhinovirus is associated with bronchiolitis, bronchitis, 
pneumonia and acute asthma exacerbation. Rhinovirus has been detected by molecular meth-
ods in 10–30% of hospitalized children with lower respiratory tract infections. Rhinovirus 
is also considered to be the second most common cause of bronchiolitis after respiratory 
syncytial virus (RSV) [57]. Rhinoviruses have long been known to cause common colds and 
exacerbations of Chronic obstructive pulmonary disease (COPD), but because rhinoviruses 
grow poorly at 37°C lower respiratory tract infections were thought to be rare. However, it 
has been demonstrated that rhinoviruses can replicate at body temperature and infect cells 
of the lower respiratory tract. Molecular studies have consistently identified rhinoviruses in 
nasopharyngeal or pharyngeal specimens from children and adults with lower respiratory 
tract infections. Rhinovirus has also been detected in 2–17% of adults and 4–45% of children 
with CAP [58].
5.12. Varicella-zoster virus
Varicella-zoster virus (VZV) is a highly contagious herpes virus and primary infection mani-
fests as chickenpox. The reactivation in later life results in zoster (shingles). It is spread by 
the respiratory route or direct contact with skin lesions. This pneumonia is rare in other-
wise healthy children but does occur in immunocompromised children causing life-threat-
ening complications [59]. VZV-related community-acquired pneumonia (VZV-CAP) has 
become increasingly recognized as a very serious and life-threatening complication invasive 
mechanical ventilation in more than half of the cases. Complications include secondary bac-
terial infections, encephalitis, hepatitis, and, with concomitant aspirin use, Reye syndrome. 
VZV pneumonia also tends be more severe in individuals who smoke. In fatal cases of pneu-
monia, laboratory findings include extensive alveolar hemorrhage, pulmonary edema and 
mononuclear cell infiltration with histological evidence of intranuclear inclusion bodies.
Varicella-zoster virus pneumonia is a serious complication of disseminated varicella-zoster 
virus infection with mortality rates of 9–50%. In adults prevalence of varicella-zoster virus 
pneumonia has varied from 5 to 50% of all varicella infections. Varicella-zoster virus is a 
self-limited benign disease in children known as chickenpox. But in adults it causes signifi-
cant complications such as varicella-zoster virus pneumonia and over 90% of cases occur in 
patients with lymphoma and immunocompromised patients. Patients exhibit diffuse alveo-
lar damage, spherical nodules are seen throughout the lung parenchyma. The nodules are 
composed of an outer fibrous capsule enclosing areas of necrotic tissue [60].
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5.13. Zoonotic viral pneumonias
Zoonotic viral pneumonias include those caused by avian influenza, hantavirus, severe 
acute respiratory syndrome (SARS), and H1N1 (swine) influenza. In 1997, an influenza 
virus (H5N1 virus) which normally only infects only birds was found to infect humans 
In Hong Kong. Manifestations included pneumonia, which in some cases led to fatal 
acute respiratory distress syndrome (ARDS) or multisystem organ failure. The rising 
incidence and widespread reporting of disease from H5N1 influenza viruses can prob-
ably be attributed to the increasing spread of the virus from existing reservoirs in domes-
tic waterfowl and live bird markets, leading to greater environmental contamination 
[61]. Recombinations of viruses in animals are a global concern. The H5N1 outbreak in 
Southeast Asia, H3N2 variant in the USA in 2012, and H7N9 avian cases in China 2013 are 
examples of such new threats. Effective surveillance is required to monitor such develop-
ments [62].
There is a growing danger that in the future avian influenza, a subtype of influenza A, may result 
in a worldwide pandemic. A/H5N1 exhibits several serious characteristics, such as increased 
virulence and human-to-human transmission in some cases, rather than bird-to-human trans-
mission. The disease causes high morbidity and mortality due to pneumonia and respiratory 
failure [63].
H1N1 was first reported in Mexico and spread to the United States. The infection from a novel 
swine-origin influenza A (H1N1) virus rapidly spread to become a worldwide pandemic in 
2009. Virus-associated hemophagocytic syndrome may play an important role in develop-
ment of multiorgan failure and ensuing death in H1N1 infection [64].
SARS is a respiratory infection caused by a coronavirus, which appears to have jumped from 
animals to humans. The disease was first reported in China in 2003 and rapidly spread from 
to the rest of the world in a 1 year period. It resulted in more than 8000 patients in 29 countries 
causing 774 deaths [65].
5.14. Co-infections
Co-infection Infections involving both respiratory bacteria and viruses or are common. Viral 
infection usually occurs first, followed by a secondary bacterial infection, as observed in the 
influenza pandemics of 1918, 1957, and 1968 where most deaths occurred due to secondary 
bacterial infection. In some infections however, especially H5N1 avian influenza, the associ-
ated pneumonia appears to be caused by direct viral action.
Co-infections are particularly common in 45% of children with CAP, and mainly involve 
pneumococcus [66], Mycoplasma pneumoniae and several species of Chlamydophila. CAP of 
mixed etiology has been characterized less in adults than in children, and prevalence is esti-
mated at less than 5%. The most common combinations reported are pneumococcus with 
rhinovirus or influenza A virus [67].
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6. Laboratory testing
Laboratory diagnosis of viral pneumonia has relied on detection of virus or viral antigen in 
upper-respiratory specimens (e.g., nasopharyngeal aspirates) and lower respiratory samples 
(e.g., induced sputum) by culture or immunofluorescence microscopy.
Traditional microbiological methods for detection of respiratory tract pathogens are relatively 
slow, often are not sensitive and are influenced by previous antibiotic therapy. Molecular 
diagnostics on the other hand hold much potential for detection of both common and atypical 
pathogens causing CAP. Analysis can be completed in hours, rather than days, for detection 
of typical pathogens and weeks for detection of atypical pathogens [68].
There are >200 known respiratory viruses, but accurate data on how many are etiological 
agents in CAP are lacking. The discovery of 6 new respiratory viruses since 2000—including 
metapneumovirus (hMPV), the severe acute respiratory syndrome coronavirus, influenza 
virus strain H5N1, coronavirus strains NL63 and Hku1, and human bocavirus—has pre-
sented new challenges for comprehensive viral diagnostics [69]. The significance of respira-
tory viral infections in patients with sepsis is underestimated. During the winter season, 
viral such as coronavirus, influenza A virus, human metapneumovirus, and respiratory syn-
cytial virus are clinically underdiagnosed in 70% of patients detected by the multiplex PCR 
assay [70].
Quantitative multiplex PCR testing of respiratory secretions is recognized as a highly sensi-
tive method for the diagnosis with the ability to detect viral pathogens and atypical bacterial 
pathogens. An acute viral infection can be confirmed with detection of influenza virus, para-
influenza virus, RSV, or hMPV. The presence of nucleic acid from adenoviruses, bocaviruses, 
coronaviruses or rhinoviruses is often found in asymptomatic persons. In the future the study 
of the virus concentration over time will contribute to distinguishing acute infections from 
protracted nucleic acid excretion [71].
7. Treatment
Antiviral drugs have been developed targeting viral proteins that can be inhibited by small 
molecular receptors or larger biotherapeutics. Consequently, most approved antiviral drugs 
are highly specific for a particular virus or family of viruses (e.g., neuraminidase inhibitors 
and adamantanes for influenza). The benefits of this approach are that there is greater selec-
tivity and may lower the risk of adverse host effects. The disadvantages are that there is a 
limited antiviral spectrum, and greater risk of antiviral resistance [72].
Treatment of Influenza Virus Neuraminidase, is essential interrupting intercellular viral 
propagation. Selective inhibitors, e.g., oseltamivir, peramivir, and zanamivir have been used 
to prevent infection during the first 24–72 hours, improving clinical symptoms and reduc-
ing morbidity and mortality. Reductions in the incidence of pneumonia in patients has been 
observed in numerous studies who received treatment in the early stages of infection [73].
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Virus family Virus Morphology Treatment Prevention Seasonality
Adenoviridae Adenoviruses 90–100 nm, non-
envelope, icosahedral 
nucleocapsid, double-
stranded DNA
Cidofovir and brincidofovir Hand hygiene, oral 
vaccine for military 
recruits
All year
Coronaviridae (Coronaviruses)—SARS, MERS 75–160 nm, envelope, 
helical, nucleocapsid, 
ssRNA (positive sense)
Supportive therapy Preventive measures,  
e.g., hand hygiene
Winter
Bunyaviridae (Arboviruses)—Hantavirus 90–100 nm, envelope 
spherical virions. 
RNA- single stranded
Supportive therapy Preventive measures,  
e.g., limit vector  
breeding
Widespread, 
all year
Herpesviridae Herpes simplex virus 1 (HSV-1) herpes simplex 
virus 2 (HSV-2), herpesvirus 6, herpesvirus 7, 
and herpesvirus 8 Varicella-zoster virus (VZV), 
Cytomegalovirus (CMV), Epstein-Barr virus 
(EBV)
130-300 nm, 
enveloped, double-
stranded DNA
Acyclovir, ganciclovir, and 
foscarnet
V-Z immunoglobulin 
Intravenous 
immunoglobulin  
Vaccine
All year
Orthomyxoviridae (Orthomyxoviruses)—Influenza A,B virus, 
H1N1
200–300 nm enveloped 
pleomorphic RNA 
single stranded
Oseltamivir, peramivir, 
zanamivir, amantadine,  
and rimantadine
Influenza vaccine 
chemoprophylaxis
End of 
autumn and 
winter
Papovaviridae (Polyomavirus)—JC virus, BK virus 18–28 nm non-
envelope Icosahedral 
DNA single strand
Limited treatments,  
surgical removal
Vaccines, e.g., Gardasil, 
Cervarix
All year
Paramyxoviridae (Paramyxoviruses)—parainfluenza virus, 
respiratory syncytial virus (RSV), human 
metapneumovirus (hMPV), measles virus
150–200 nm, 
enveloped helical 
symmetry RNA-
negative strand
Ribavirin protease inhibitors 
(e.g., lopinavir/ritonavir) 
Ribavirin
Preventive measures, 
measles vaccination 
for immune serum 
immunoglobulin
End of 
autumn, 
beginning of 
winter
Picornaviridae (Picornaviruses)—enteroviruses, 
coxsackievirus, echovirus, enterovirus 71, 
rhinovirus
20–30 nm non-
envelope cubic 
symmetry RNA-
positive strand
Pleconaril Alfa interferon 
(intranasal)
All year
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Virus family Virus Morphology Treatment Prevention Seasonality
Retroviridae (Retroviruses)—human immunodeficiency 
virus (HIV), human lymphotropic virus type 1 
(HTLV-1)
80–100 nm envelope 
helical RNA-single 
strand
Nucleoside reverse 
transcriptase inhibitors 
(NRTIs), protease inhibitor 
(PI), non-nucleoside reverse 
transcriptase inhibitor 
(NNRTI)
Education, preventive 
measures
All year
Table 1. Characteristic features of viral pathogens causing pneumonia.
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Laninamivir octanoate, a new neuraminidase inhibitor administered by inhalation, can be 
effective in the treatment of IV infection, including oseltamivir-resistant strains. They are 
exclusively specific to influenza virus type A. However, side effects and rapid development 
of resistances, has meant that they have fallen into disuse. Immunomodulators are also being 
studied for reducing viral-mediated inflammation and its effect on the host [74].
Ribavirin has shown effectiveness in the management of acute episodes of pneumonia or for 
improving respiratory parameters during recovery. Meta-analysis studies performed in chil-
dren, indicated that inhaled ribavirin can reduce hospital stay and time on ventilator times 
during pneumonia, however, the overall mortality rates are not affected. Ribavirin has also 
been used in severely immunocompromised patients, e.g., lung transplant recipients with 
positive outcomes. General use of bronchodilators, antibiotics, or corticosteroids are not rec-
ommended in the American pediatric guidelines for SRV bronchiolitis [75].
Acyclovir (Zovirax), inhibits viral DNA synthesis by competitively binding to viral DNA poly-
merase. Due to poor absorption, intravenous acyclovir at a dosage of 250 mg/m2 every 8 hours 
is currently the treatment of choice for HSV pneumonia. The dosage of acyclovir should be 
decreased in patients with underlying renal insufficiency. Adverse reactions are infrequent, 
but renal impairment secondary to precipitation of acyclovir in the tubules can occur in 5–10% 
of patients if not properly rehydrated. Having a proven HSV pneumonia appears to be associ-
ated with high morbidity in solid tumor patients. This group of patients have been shown to 
benefit from acyclovir therapy [76]. There is little doubt that intravenous acyclovir is beneficial 
in the rare cases of varicella-zoster pneumonia in immunocompromised patients.
Supportive treatment was only available for other respiratory viruses until recently, However, 
some antiviral drugs are currently under investigation. Cidofovir is an acyclic nucleoside 
phosphonate analog of cytidine monophosphate. Upon conversion to its diphosphate form it 
leads to viral DNA chain termination. Limitations of cidofovir include poor cellular uptake 
and nephrotoxicity. Brincidofovir, a derivative of cidofovir which is active against double-
stranded DNA viruses, is a major improvement in anti-adenovirus therapy [77]. Lung trans-
plant recipients with metapneumovirus infections have been treated with success using 
intravenous ribavirin. Rhinovirus and Enterovirus, have been successfully used in limited 
studies using Pleconaril, which is incorporated into the virus capsid (Table 1) [78].
8. Prevention
Measures in infectious infection control, particularly of the respiratory tract, involve using bar-
rier methods preventing infection. Use of gloves, masks and hand-washing have been shown 
to be effective in reducing transmission rates in the health care centers. Isolation of patients 
during the clinical phase of the disease is also strongly recommended and reduces overall 
incidence. Immunization plays a very important role in prevention, but is only available for 
a few viruses. As the population ages and rates of pneumonia increase. Hospitalizations for 
pneumonia will continue to show an upward trend unless effective intervention strategies are 
devised and implemented. This includes recommending immunization with PPV and annual 
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influenza vaccinations. Although the effectiveness of these vaccines decreases with age and 
comorbid conditions [79].
9. Future strategies
Vaccines are still considered the great hope in disease prevention and control strategies. 
However, among respiratory viruses there has been little progress, only influenza has vac-
cines. A different approach is needed in developing new vaccines with longer term efficacy and 
broader response. Current vaccines are prone to changing antigenicity and need to be admin-
istered annually. Vaccine development has been in progress for decades but faces numerous 
technical challenges. Respiratory viruses such as RSV, PIV and hMPV initiate incomplete 
immune responses and so reinfections tend to occur. The pace of progress is slow both for Both 
live-attenuated and subunit vaccines. It may be years before such vaccines are available in the 
market place. However, once available then adult immunization may offer protection to young 
infants as is the case with influenza vaccines [80].
9.1. Stem cell
Stem cells are unique in that they possess the capacity to self-renew and capable of differentia-
tion into many cell types hence leading to the regeneration of injured organs. In lung injury, 
stem cells have been shown to promote endothelial and epithelial repair by engrafting into 
tissue and interacting with neighboring cells. Furthermore, stem cells beneficially influence 
the host’s immune response by reducing harmful inflammatory reactions. Paracrine media-
tors and mitochondria-containing micro-vesicles released by stem cells appear responsible for 
the beneficial effects on immune responses and cellular functions [81].
9.2. Gene expression
Gene expression profiles of peripheral blood leukocytes can differentiate viral from bacterial 
infections with 95% accuracy. They can also identify unique profiles in patients with bacterial 
and viral respiratory tract infections. Application of gene expression profile analysis in chil-
dren with CAP can significantly enhance the ability to classify patients according to the class 
of pathogen causing the infection and disease severity. Molecular distance to health (MDTH) 
is a novel metric that in a single score can provide a global assessment of the perturbation of 
the patient immune profile compared to healthy controls. It has been shown to accurately 
classify the severity of the disease in for example cases of bacterial sepsis, staphylococcal 
infections, as well as in children with respiratory viral infections [82].
Author details
Al Johani Sameera* and Akhter Javed
*Address all correspondence to: johanis@ngha.med.sa
King Abdulaziz Medical City, Riyadh, Saudi Arabia
Contemporary Topics of Pneumonia206
References
[1] Prioreschi P. A history of medicine. In: vol II: Greek Medicine, chapter five, "Hippocrates". 
2nd ed. NE: Horatius Press; 1996. p. 201-205
[2] Centers for Disease Control and Prevention. Klebsiella pneuminae in Healthcare Settings. 
Available at: http://www.cdc.gov/HAI/organisms/klebsiella/klebsiella.htm
[3] Austrian R. The Gram stain and the etiology of lobar pneumonia, an historical note. 
Bacteriological Reviews. 1960;24(3):261-265
[4] Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H, WHO Child Health Epidemiology 
Reference Group. Global estimate of the incidence of clinical pneumonia among children 
under five years of age. Bulletin of the World Health Organization. 2004;356:895-903
[5] Musher D, Anna R, Thorner AR. Community-acquired pneumonia. The New England 
Journal of Medicine. 2014;371:1619-1628
[6] File TM, Marrie TJA. Burden of community-acquired pneumonia in North American 
adults. Postgraduate Medicine. 2010;122(2):130-141
[7] Haq IJ, Battersby AC, Eastham K, McKean M. Community acquired pneumonia in children. 
BMJ. 2017;356:j686
[8] Alcón A, Fàbregas N, Torres A. Pathophysiology of pneumonia. Clinics in Chest Medicine. 
2005;26(1):39-46
[9] Lee KH, Gordon A, Foxman B. The role of respiratory viruses in the etiology of bacterial 
pneumonia: An ecological perspective. Evolution, Medicine and Public Health. 2016; 
2016(1):95-109
[10] Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune 
defenses. Clinical Microbiological Reviews. 2009;22(2):240-273
[11] Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbal-
ance in acute respiratory syncytial virus bronchiolitis. American Journal of Respiratory 
and Critical Care Medicine. 2003;168(6):633-639
[12] Wack A, Openshaw P, Ogarra A. Contribution of cytokines to pathology and protection 
in virus infection. Current Opinion in Virology. 2011;1(3):84-195
[13] Cauley LS, Vella AT. Why is coinfection with influenza virus and bacteria so difficult to 
control? Discovery Medicine. 2015;19(102):33-40
[14] Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiol-
ogy of childhood pneumonia. Bulletin of the World Health Organization. 2008;86:408-16.3
[15] Blasi F, Aliberti S, Pappalettera M, Tarsia P. 100 years of respiratory medicine: pneumonia. 
Respiratory Medicine. 2007;101(5):875-881
[16] Farshad N, Saffar MJ, Khalilian AR, et al. Respiratory viruses in hospitalized chil-
dren with acute lower respiratory tract infections, Mazandaran Province, Iran. Indian 
Pediatrics. 2008;45:590-592
Pneumonia of Viral Etiologies
http://dx.doi.org/10.5772/intechopen.71608
207
[17] Ozbay B, Sertoğullarindan B, Tekin M, et al. Influenza-associated pneumonia in a Turkish 
area with endemic avian influenza. Respirology. 2008;13:444-446
[18] Saudi Arabia: Influenza and Pneumonia. LeDuc Media, USA: WHO; May 2014. http://
www.worldlifeexpectancy.com/saudi-arabia-influenza-pneumonia
[19] Saeed AA, Abedi GR, Alzahrani AG, Salameh I, Abdirizak F, Alhakeem R, Algarni H, El Nil 
OA, Mohammed M, Assiri AM, Alabdely HM, Watson JT, Gerber SI. Surveillance and test-
ing for Middle East respiratory syndrome coronavirus, Saudi Arabia, April 2015-February 
2016. Emerging Infectious Diseases. 2017 Apr;23(4):682-685
[20] Shapiro M, London B, Nigri D, Shoss A, Zilber E, Fogel I. Middle East respiratory syndrome 
coronavirus: Review of the current situation in the world. Disaster and Military Medicine. 
2016; May 4;2:9
[21] Middle East Respiratory Syndrome cCronavirus (MERS-CoV)—Saudi Arabia. World 
Health Organization; Feb 29, 2016 http://www.who.int/csr/don/29-february-2016-mers- 
saudi-arabia/en/
[22] Chen X, Chughtai AA, Dyda A, MacIntyre CR. Comparative epidemiology of Middle 
East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia and South Korea. 
Emerging Microbes and Infection. 2017;6(6):e51
[23] Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H. Global estimate of the incidence of 
clinical pneumonia among children under five years of age. Bulletin of the World Health 
Organization. 2004;82:895-903
[24] Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distri-
bution of child deaths from acute respiratory infections. The Lancet Infectious Diseases. 
2002;2:25-32
[25] Chang AB, Brown N, Toombs M, Marsh RL, Redding GJ. Lung disease in indigenous 
children. Paediatric Respiratory Reviews. 2014;15(4):325-332
[26] Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired 
pneumonia requiring hospitalization among U.S. adults. The New England Journal 
of Medicine. 2015;373(5):415-427
[27] Rozenbaum MH, Marie-Josee J, Mangen MJJ, Huijts SM, Van Der Werf TS, Postma 
MJ. Incidence, direct costs and duration of hospitalization of patients hospitalized with 
community acquired pneumonia: A nationwide retrospective claims database analysis. 
Vaccine. 2015;33(28):3193-3199
[28] Trotter CL, Stuart JM, George R, Miller E. Increasing Hospital Admissions for Pneumonia, 
England. Emerging Infectious Diseases. 2008;14(5):727-733. DOI: 10.3201/eid1405.071011
[29] Waterer GW. Diagnosing viral and atypical pathogens in the setting of community-
acquired pneumonia. Clinics in Chest Medicine. 2017;38(1):21-28
Contemporary Topics of Pneumonia208
[30] Sharma L, Losier A, Tolbert T, Dela Cruz CS, Marion CR. Atypical pneumonia: Updates on 
Legionella, Chlamydophila, and Mycoplasma Pneumonia. Clinics in Chest Medicine. 2017; 
38(1):45-58
[31] Parrott GL, Kinjo T, Fujita J. A compendium for Mycoplasma pneumoniae. Frontiers in 
Microbiology. 2016;7:513. DOI: 10.3389/fmicb.2016.00513
[32] Cunha BA, Burillo A, Bouza E. Legionnaires' disease. Lancet. 2016;387(10016):376-385
[33] Smyth A. Pneumonia due to viral and atypical organisms and their sequelae: Childhood 
respiratory infections. British Medical Bulletin. 2002;61(1):247-262
[34] Walter JM, Wunderink RG. Severe Respiratory Viral Infections: New Evidence and Changing 
Paradigms. Infectious Disease Clinics of North America. 2017;Jul 5. pii:S0891-5520(17)30034-
X. DOI: 10.1016/j.idc.2017.05.004 [Epub ahead of print]
[35] Burk M, El-Kersh K, Saad M, Wiemken T, Ramirez J, Cavallazzi RA. Viral infection 
in community-acquired pneumonia: A systematic review and meta-analysis. European 
Respiratory Review. 2016;25(140):178-188
[36] Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clinical Micro-
biology Reviews. 2000;13(3):371-384
[37] Ison MG, Hayden RT. Adenovirus. Microbiology Spectrum. 2016 Aug;4(4):217-232. DOI: 
10.1128/microbiolspec.DMIH2-0020-2015.
[38] Lamson DM, Kajon A, Shudt M, Girouard G, St. George K. Detection and genetic charac-
terization of adenovirus type 14 strain in students with influenza-like illness, New York, 
USA, 2014-2015. Emerging Infectious Diseases. 2017;23(7):1194-1197. DOI: 10.3201/
eid2307.161730.
[39] Zahradnik JM. Adenovirus pneumonia. Seminars in Respiratory Infections. 1987;2(2): 
104-111
[40] Dingyu Tan, Huadong Zhu, Yangyang Fu, Fei Tong, Dongqi Yao, Joseph Walline, Jun Xu, 
Xuezhong Yu. Severe Community-Acquired Pneumonia Caused by Human Adenovirus 
in Immunocompetent Adults: A Multicenter Case Series. Published: March 11, 2016. 
https://doi.org/10.1371/journal.pone.0151199
[41] Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant 
recipients. Blood. 2009;113(23):5711-5719. DOI: 10.1182/blood-2008-10-143560
[42] Corona-Nakamura AL, Arias-Merino MJ. In: Price P, editor. Management of CMV-
Associated Diseases in Immunocompromised Patients, Manifestations of Cytomegalovirus 
Infection. InTech; 2013. DOI: 10.5772/56141 Available from: https://www.intechopen.com/ 
books/manifestations-of-cytomegalovirus-infection/management-of-cmv-associated- 
diseases-in-immunocompromised-patients
[43] Perk M, Marrie TJ. Epstein-Barr virus pneumonia. In: Marrie TJ, editor. Community-
Acquired Pneumonia. Boston, MA: Springer; 2002
Pneumonia of Viral Etiologies
http://dx.doi.org/10.5772/intechopen.71608
209
[44] Jain M, Duggal S, Chugh TD. Cytomegalovirus infection in non-immumosuppressed 
critically ill patients. Journal of Infection in Developing Countries. 2011;5(8):571-579
[45] C1 C, Sidoti F, Saldan A, Sinesi F, Balloco C, Simeone S, Lorusso M, Mantovani S, Merlino C, 
Solidoro P, Cavallo R. Clinical impact of HSV-1 detection in the lower respiratory tract from 
hospitalized adult patients. Clinical Microbiology and Infection. 2012;18(8):E305-E307
[46] Van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovi-
rus isolated from young children with respiratory tract disease. Nature Medicine 2001; 
7:719.
[47] Bénet T, Picot VS, Awasthi S, Pandey N, Bavdekar A, Kawade A, Robinson A, Rakoto-
Andrianarivelo M, Sylla M, Diallo S, Russomando G, Basualdo W, Komurian-Pradel F, 
Endtz H, Vanhems P, Paranhos-Baccalà G, For The Gabriel Network. Severity of pneumonia 
in under 5-year-old children from developing countries: A multicenter, prospective, obser-
vational study. The American Journal of Tropical Medicine and Hygiene. 2017;97(1):68-76
[48] Joseph C, Togawa Y, Shindo N. Bacterial and viral infections associated with influenza. 
Influenza and Other Respiratory Viruses. 2013;7(2):105-113
[49] Mauskopf J, Klesse M, Lee S, Herrera-Taracena G. The burden of influenza complications 
in different high-risk groups: A targeted literature review. Journal of Medical Economics. 
2013;16(2):264-277
[50] Moss WJ. Measles. Lancet. 2017 Jun 30. pii: S0140-6736(17)31463-0. DOI: 10.1016/S0140- 
6736(17)31463-0
[51] Rota PA, Moss WJ, Takeda M, de Swart RL, Thompson KM, Goodson JL. Measles. Nature 
Reviews Disease Primers. 2016;2:16049
[52] Pawełczyk M, Kowalski ML. The role of human parainfluenza virus infections in the 
immunopathology of the respiratory tract. Current Allergy and Asthma Reports. 2017 
Mar;17(3):16. DOI: 10.1007/s11882-017-0685-2.A
[53] Branche AR, Falsey AR. Parainfluenza virus infection. Seminars in Respiratory and 
Critical Care Medicine. 2016;37(4):538-554
[54] Hall CB. Respiratory syncytial virus and parainfluenza virus. The New England Journal 
of Medicine. 2001;344:1917-1928
[55] Pastula ST, Hackett J, Coalson J, Jiang X, Villafana T, Ambrose C, Fryzek J. Hospitalizations 
for Respiratory Syncytial Virus Among Adults in the United States, 1997-2012. Open Forum 
Infectious Diseases. 2017 Jan 9;4(1):1-7. DOI: 10.1093/ofid/ofw270 eCollection 2017 Winter
[56] Drysdale SB, Mejias A, Ramilo O. Rhinovirus—Not just the common cold. The Journal of 
Infection. 2017;74(1):S41-S46
[57] Xiao Q, Zheng S, Zhou L, Ren L, Xie X, Deng Y, Tian D, Zhao Y, Fu Z, Li T, Huang A, Liu E. 
Impact of human rhinovirus types and viral load on the severity of illness in hospitalized 
children with lower respiratory tract infections. The Pediatric Infectious Disease Journal. 
2015;34(11):1187-1192
Contemporary Topics of Pneumonia210
[58] Pavia AT. What is the role of respiratory viruses in community acquired pneumonia; 
What is the best therapy for influenza and other viral causes of CAP? Infectious Disease 
Clinics of North America. 2013;27(1):157-175. DOI: 10.1016/j.idc.2012.11.007.
[59] Heininger U, Seward JF. Varicella. Lancet. 2006;368(9544):1365-1376
[60] Mirouse A, Vignon P, Piron P, Robert R, Papazian L, Géri G, Blanc P, Guitton C, Guérin C, 
Bigé N, Rabbat A, Lefebvre A, Razazi K, Fartoukh M, Mariotte E, Bouadma L, Ricard JD, 
Seguin A, Souweine B, Moreau AS, Faguer S, Mari A, Mayaux J, Schneider F, Stoclin A, 
Perez P, Maizel J, Lafon C, Ganster F, Argaud L, Girault C, Barbier F, Lecuyer L, Lambert J, 
Canet E. Severe varicella-zoster virus pneumonia: A multicenter cohort study. Critical Care. 
2017;21(1):137. DOI: 10.1186/s13054-017-1731-.0
[61] Gao R, Cao B, Hu Y, Feng Z, Wang D. Human infection with a novel avian-origin influ-
enza A (H7N9) virus. The New England Journal of Medicine. 2013;368:1888-1897
[62] Medina RA, Garcia-Sastre A. Influenza A viruses: New research developments. Nature 
Reviews. Microbiology. 2011;9:590-603
[63] Cunha BA. Swine influenza (H1N1) pneumonia: Clinical considerations. Infectious 
Disease Clinics of North America. 2010;24:203-228
[64] Mena I, Nelson MI, Quezada-Monroy F, Dutta J, Cortes-Fernández R, Lara-Puente JH, 
Castro-Peralta F, Cunha LF, Trovão NS, Lozano-Dubernard B, Rambaut A, Van Bakel H, 
García-Sastre A. Origins of the 2009 H1N1 influenza pandemic in swine in Mexico. eLife. 
2016;5:1-21. DOI: 10.7554/eLife.16777
[65] Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a 
cause of death in pandemic influenza: Implications for pandemic influenza prepared-
ness. The Journal of Infectious Diseases. 2008;198:962-970
[66] Johnstone J, Majdumar SR, Fox JD, Marrie TJ. Viral infections in adults hospitalized 
with community-acquired pneumonia: Prevalence, pathogens, and presentation. Chest. 
2008;134:1141-1148
[67] Gadsby NJ, Russell CD, McHugh MP, Mark H, Conway Morris A, Laurenson IF, et al. 
Comprehensive molecular testing for respiratory pathogens in community-acquired 
pneumonia. Clinical Infectious Diseases. 2016;62(7):817-823
[68] Murdoch DR. How recent advances in molecular tests could impact the diagnosis of 
pneumonia. Expert Review of Molecular Diagnostics. 2016;16(5):533-540
[69] Berry M, Gamieldien J, Fielding BC. Identification of new respiratory viruses in the new 
millennium. Viruses. 2015;7(3):996-1019
[70] Ljungström LR, Jacobsson G, Claesson BEB, Andersson R, Enroth H. Respiratory viral 
infections are underdiagnosed in patients with suspected sepsis. European Journal of 
Clinical Microbiology & Infectious Diseases. 17-05-2017. DOI: 10.1007/s10096-017-2990-z 
[Epub ahead of print]
Pneumonia of Viral Etiologies
http://dx.doi.org/10.5772/intechopen.71608
211
[71] Krause JC, Panning M, Hengel H, Henneke P. The role of multiplex PCR in respiratory 
tract infections in children. Deutsches Ärzteblatt International. 2014;111(38):639-645
[72] Hermann T. Small molecules targeting viral RNA. WIREs RNA. 2016. DOI: 10.1002/
wrna.1373
[73] Kamali A, Holodniy M. Influenza treatment and prophylaxis with neuraminidase inhib-
itors: A review. Infection and Drug Resistance. 2013;6:187-198
[74] Watanabe SC, Chang MJ, Kim DW, Chu YO, MARVEL Study Group. Long-acting neur-
aminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: 
a double-blind, randomized, noninferiority clinical trial. Clinical Infectious Diseases. 
2010;51:1167-1175
[75] Galván JM, Rajas O, Aspa J. Review of non-bacterial infections in respiratory medicine: 
Viral pneumonia. Archivos de Bronconeumología. 2015;51(11):590-597
[76] GM1 A, Torres HA, Tarrand J, Safdar A, Bodey G, Chemaly RF. Herpes simplex virus 
lower respiratory tract infection in patients with solid tumors. Cancer. 2009;115(1):199-
206. DOI: 10.1002/cncr.24011
[77] Wold WSM, Toth K. New drug on the horizon for treating adenovirus. Expert Opinion 
on Pharmacotherapy. 2015;16(14):2095-2099
[78] Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW. Susceptibilities of enterovirus 
D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antiviral 
Research. 2016;131:61-65
[79] Assaad U, El-Masri I, Porhomayon J, El-Solh AA. Pneumonia immunization in older 
adults: Review of vaccine effectiveness and strategies. Clinical Interventions in Aging. 
2012;7:453-461. DOI: 10.2147/CIA.S29675
[80] Rey-Jurado E, Kalergis AM. Immunological features of respiratory syncytial virus-
caused pneumonia—Implications for vaccine design. International Journal of Molecular 
Sciences. 2017;18(3):556. DOI: 10.3390/ijms18030556.
[81] Hogan BLM, Barkauskas CE, Chapman HA, Epstein JA, Jain R, Hsia CCW, Niklason L, 
Calle E, Le A, Randell SH, Rock J, Snitow M, Krummel M, Stripp BR, Vu T, White ES, 
Whitsett JA, Morrisey EE. Repair and regeneration of the respiratory system: Complexity, 
plasticity, and mechanisms of lung stem cell function. Cell Stem Cell. 2014;15(2):123-138
[82] Xu X, Yuan B, Liang Q, et al. Gene expression profile analysis of ventilator-associated pneu-
monia. Molecular Medicine Reports. 2015;12(5):7455-7462. DOI: 10.3892/mmr.2015.4389
Contemporary Topics of Pneumonia212
